FY2029 EPS Estimates for EDAP TMS Lowered by HC Wainwright

Key Points

• HC Wainwright has lowered its FY2029 earnings per share (EPS) estimates for EDAP TMS to $0.20, down from $0.31, while the current consensus estimate stands at ($0.60) per share.
• While some analysts have issued a "hold" rating, the stock's average rating remains "hold," with a target price of $8.50.
• Institutional investors own nearly 62.74% of EDAP TMS's shares, indicating significant interest from large investment firms.

EDAP TMS S.A. (NASDAQ:EDAP - Free Report) - Analysts at HC Wainwright decreased their FY2029 earnings per share (EPS) estimates for EDAP TMS in a research report issued on Friday, August 29th. HC Wainwright analyst S. Ramakanth now forecasts that the medical equipment provider will earn $0.20 per share for the year, down from their previous estimate of $0.31. The consensus estimate for EDAP TMS's current full-year earnings is ($0.60) per share.

Other equities analysts also recently issued reports about the company. Wall Street Zen started coverage on EDAP TMS in a report on Thursday, May 15th. They issued a "hold" rating on the stock. Piper Sandler downgraded EDAP TMS from an "overweight" rating to a "neutral" rating in a report on Thursday, May 15th. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $8.50.

EDAP TMS Stock Performance

NASDAQ EDAP opened at $2.26 on Monday. The business's 50-day moving average price is $1.50 and its 200 day moving average price is $1.83. EDAP TMS has a twelve month low of $1.21 and a twelve month high of $3.77. The company has a market capitalization of $84.50 million, a PE ratio of -3.70 and a beta of -0.21. The company has a current ratio of 1.51, a quick ratio of 1.05 and a debt-to-equity ratio of 0.04.

Institutional Investors Weigh In On EDAP TMS

Large investors have recently modified their holdings of the stock. Millennium Management LLC grew its stake in EDAP TMS by 218.5% during the 4th quarter. Millennium Management LLC now owns 48,915 shares of the medical equipment provider's stock valued at $108,000 after purchasing an additional 33,558 shares in the last quarter. BNP Paribas Financial Markets grew its stake in EDAP TMS by 111.5% during the 4th quarter. BNP Paribas Financial Markets now owns 48,650 shares of the medical equipment provider's stock valued at $108,000 after purchasing an additional 25,650 shares in the last quarter. Cetera Investment Advisers grew its stake in EDAP TMS by 33.9% during the 1st quarter. Cetera Investment Advisers now owns 75,000 shares of the medical equipment provider's stock valued at $147,000 after purchasing an additional 19,000 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its stake in EDAP TMS by 48.5% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 160,800 shares of the medical equipment provider's stock valued at $355,000 after purchasing an additional 52,500 shares in the last quarter. Finally, Sage Mountain Advisors LLC acquired a new stake in EDAP TMS during the 2nd quarter valued at approximately $165,000. Institutional investors and hedge funds own 62.74% of the company's stock.

About EDAP TMS

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.